IL4R and Alzheimer disease: It is recommended that when using anti-IL-4Rα monoclonal antibody in the treatment of AD, the drug should be maintained every 2–4 weeks for a long period, with a gradual extension of the dosing interval after reaching EASI 90 or IGA 0/1.